AtriCure, Inc. (NASDAQ: ATRC) Stock Competitors & Peer Comparison
See ATRC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ATRC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ATRC | $56.44 | -2.31% | 2.9B | 1747.20 | $0.03 | N/A |
| ISRG | $449.53 | -2.39% | 156B | 46.78 | $9.62 | N/A |
| BDX | $213.50 | -0.82% | 57.9B | 16.35 | $13.00 | +1.86% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +1.86% |
| MDLN | $42.40 | +4.16% | 35.9B | 29.98 | $1.36 | N/A |
| RMD | $236.77 | +0.44% | 32.9B | 20.31 | $11.53 | +1.06% |
| WST | $413.10 | +0.07% | 28.7B | 44.86 | $9.20 | +0.22% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $89.33 | -1.22% | 15.3B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.86% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
ATRC vs ISRG Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, ISRG has a market cap of 156B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while ISRG trades at $449.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas ISRG's P/E ratio is 46.78. In terms of profitability, ATRC's ROE is +0.03%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, ATRC is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
ATRC vs BDX Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, BDX has a market cap of 57.9B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while BDX trades at $213.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas BDX's P/E ratio is 16.35. In terms of profitability, ATRC's ROE is +0.03%, compared to BDX's ROE of +0.04%. Regarding short-term risk, ATRC is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
ATRC vs BDXA Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas BDXA's P/E ratio is 45.70. In terms of profitability, ATRC's ROE is +0.03%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, ATRC is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
ATRC vs MDLN Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, MDLN has a market cap of 35.9B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while MDLN trades at $42.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas MDLN's P/E ratio is 29.98. In terms of profitability, ATRC's ROE is +0.03%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, ATRC is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check MDLN's competition here
ResMed Inc. (NYSE: RMD)
ATRC vs RMD Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, RMD has a market cap of 32.9B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while RMD trades at $236.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas RMD's P/E ratio is 20.31. In terms of profitability, ATRC's ROE is +0.03%, compared to RMD's ROE of +0.25%. Regarding short-term risk, ATRC is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check RMD's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
ATRC vs WST Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, WST has a market cap of 28.7B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while WST trades at $413.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas WST's P/E ratio is 44.86. In terms of profitability, ATRC's ROE is +0.03%, compared to WST's ROE of +0.21%. Regarding short-term risk, ATRC is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
ATRC vs HOLX Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas HOLX's P/E ratio is 31.54. In terms of profitability, ATRC's ROE is +0.03%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, ATRC is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
ATRC vs SOLV Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, SOLV has a market cap of 15.3B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while SOLV trades at $89.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas SOLV's P/E ratio is 12.69. In terms of profitability, ATRC's ROE is +0.03%, compared to SOLV's ROE of +0.03%. Regarding short-term risk, ATRC is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
ATRC vs BDXB Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas BDXB's P/E ratio is 7.60. In terms of profitability, ATRC's ROE is +0.03%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, ATRC is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
ATRC vs BAX Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, BAX has a market cap of 13.7B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while BAX trades at $26.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas BAX's P/E ratio is 12.70. In terms of profitability, ATRC's ROE is +0.03%, compared to BAX's ROE of -0.12%. Regarding short-term risk, ATRC is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
ATRC vs COO Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, COO has a market cap of 12.1B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while COO trades at $63.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas COO's P/E ratio is 13.94. In terms of profitability, ATRC's ROE is +0.03%, compared to COO's ROE of +0.07%. Regarding short-term risk, ATRC is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
ATRC vs RGEN Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, RGEN has a market cap of 11.1B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while RGEN trades at $172.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas RGEN's P/E ratio is 96.66. In terms of profitability, ATRC's ROE is +0.03%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, ATRC is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
ATRC vs AVTR Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, AVTR has a market cap of 10.6B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while AVTR trades at $15.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas AVTR's P/E ratio is 18.32. In terms of profitability, ATRC's ROE is +0.03%, compared to AVTR's ROE of +0.06%. Regarding short-term risk, ATRC is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
ATRC vs ATR Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, ATR has a market cap of 9.1B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while ATR trades at $143.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas ATR's P/E ratio is 25.19. In terms of profitability, ATRC's ROE is +0.03%, compared to ATR's ROE of +0.10%. Regarding short-term risk, ATRC is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
ATRC vs BLCO Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, BLCO has a market cap of 7.6B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while BLCO trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas BLCO's P/E ratio is 32.88. In terms of profitability, ATRC's ROE is +0.03%, compared to BLCO's ROE of -0.02%. Regarding short-term risk, ATRC is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
ATRC vs TFX Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, TFX has a market cap of 6.6B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while TFX trades at $156.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas TFX's P/E ratio is 17.76. In terms of profitability, ATRC's ROE is +0.03%, compared to TFX's ROE of +0.10%. Regarding short-term risk, ATRC is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
ATRC vs MMSI Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, MMSI has a market cap of 5.3B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while MMSI trades at $88.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas MMSI's P/E ratio is 22.46. In terms of profitability, ATRC's ROE is +0.03%, compared to MMSI's ROE of +0.10%. Regarding short-term risk, ATRC is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
ATRC vs ICUI Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while ICUI trades at $178.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas ICUI's P/E ratio is 22.74. In terms of profitability, ATRC's ROE is +0.03%, compared to ICUI's ROE of +0.03%. Regarding short-term risk, ATRC is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
ATRC vs NVST Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, NVST has a market cap of 4.1B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while NVST trades at $25.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas NVST's P/E ratio is 17.56. In terms of profitability, ATRC's ROE is +0.03%, compared to NVST's ROE of +0.21%. Regarding short-term risk, ATRC is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
ATRC vs PLSE Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, PLSE has a market cap of 4B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while PLSE trades at $56.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas PLSE's P/E ratio is -46.71. In terms of profitability, ATRC's ROE is +0.03%, compared to PLSE's ROE of -0.78%. Regarding short-term risk, ATRC is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check PLSE's competition here
Stevanato Group S.p.A. (NYSE: STVN)
ATRC vs STVN Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, STVN has a market cap of 3.7B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while STVN trades at $13.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas STVN's P/E ratio is 20.47. In terms of profitability, ATRC's ROE is +0.03%, compared to STVN's ROE of +0.09%. Regarding short-term risk, ATRC is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check STVN's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
ATRC vs XRAY Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while XRAY trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas XRAY's P/E ratio is 6.78. In terms of profitability, ATRC's ROE is +0.03%, compared to XRAY's ROE of -0.09%. Regarding short-term risk, ATRC is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check XRAY's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
ATRC vs BLFS Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas BLFS's P/E ratio is 37.49. In terms of profitability, ATRC's ROE is +0.03%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, ATRC is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
ATRC vs LMAT Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while LMAT trades at $79.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas LMAT's P/E ratio is 29.05. In terms of profitability, ATRC's ROE is +0.03%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, ATRC is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
ATRC vs AZTA Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, AZTA has a market cap of 1.8B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while AZTA trades at $48.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas AZTA's P/E ratio is 96.38. In terms of profitability, ATRC's ROE is +0.03%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, ATRC is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
ATRC vs KMTS Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, KMTS has a market cap of 1.8B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while KMTS trades at $31.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas KMTS's P/E ratio is -11.15. In terms of profitability, ATRC's ROE is +0.03%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, ATRC is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
ATRC vs STAA Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while STAA trades at $26.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas STAA's P/E ratio is 41.88. In terms of profitability, ATRC's ROE is +0.03%, compared to STAA's ROE of +0.00%. Regarding short-term risk, ATRC is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
ATRC vs ATRI Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas ATRI's P/E ratio is 64.50. In terms of profitability, ATRC's ROE is +0.03%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, ATRC is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
ATRC vs ANGO Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, ANGO has a market cap of 508.4M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while ANGO trades at $12.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas ANGO's P/E ratio is -31.00. In terms of profitability, ATRC's ROE is +0.03%, compared to ANGO's ROE of -0.19%. Regarding short-term risk, ATRC is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check ANGO's competition here
MiniMed Group, Inc. (NASDAQ: MMEDV)
ATRC vs MMEDV Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, MMEDV has a market cap of 495.6M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while MMEDV trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas MMEDV's P/E ratio is N/A. In terms of profitability, ATRC's ROE is +0.03%, compared to MMEDV's ROE of N/A. Regarding short-term risk, ATRC is less volatile compared to MMEDV. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check MMEDV's competition here
Embecta Corp. (NASDAQ: EMBC)
ATRC vs EMBC Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, EMBC has a market cap of 364.3M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while EMBC trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas EMBC's P/E ratio is 2.47. In terms of profitability, ATRC's ROE is +0.03%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ATRC is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
ATRC vs SMTI Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, SMTI has a market cap of 290.9M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while SMTI trades at $31.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas SMTI's P/E ratio is -527.67. In terms of profitability, ATRC's ROE is +0.03%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, ATRC is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
ATRC vs OSUR Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, OSUR has a market cap of 229.7M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while OSUR trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas OSUR's P/E ratio is -4.83. In terms of profitability, ATRC's ROE is +0.03%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, ATRC is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check OSUR's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
ATRC vs PDEX Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, PDEX has a market cap of 223.6M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while PDEX trades at $71.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas PDEX's P/E ratio is 19.14. In terms of profitability, ATRC's ROE is +0.03%, compared to PDEX's ROE of +0.26%. Regarding short-term risk, ATRC is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check PDEX's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
ATRC vs UTMD Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, UTMD has a market cap of 207.6M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while UTMD trades at $72.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas UTMD's P/E ratio is 21.56. In terms of profitability, ATRC's ROE is +0.03%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, ATRC is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check UTMD's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
ATRC vs NNNN Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, NNNN has a market cap of 166.8M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while NNNN trades at $4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas NNNN's P/E ratio is 25.33. In terms of profitability, ATRC's ROE is +0.03%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, ATRC is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check NNNN's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
ATRC vs KRMD Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while KRMD trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas KRMD's P/E ratio is -79.00. In terms of profitability, ATRC's ROE is +0.03%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, ATRC is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
ATRC vs STXS Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, STXS has a market cap of 105.2M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while STXS trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas STXS's P/E ratio is -6.18. In terms of profitability, ATRC's ROE is +0.03%, compared to STXS's ROE of -1.33%. Regarding short-term risk, ATRC is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
ATRC vs AKYA Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas AKYA's P/E ratio is -1.34. In terms of profitability, ATRC's ROE is +0.03%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, ATRC is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check AKYA's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
ATRC vs POCI Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, POCI has a market cap of 55.7M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while POCI trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas POCI's P/E ratio is -11.04. In terms of profitability, ATRC's ROE is +0.03%, compared to POCI's ROE of -0.24%. Regarding short-term risk, ATRC is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check POCI's competition here
SkyAI, Inc. (NASDAQ: STSS)
ATRC vs STSS Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas STSS's P/E ratio is -0.02. In terms of profitability, ATRC's ROE is +0.03%, compared to STSS's ROE of -0.99%. Regarding short-term risk, ATRC is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
ATRC vs OMIC Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas OMIC's P/E ratio is -0.58. In terms of profitability, ATRC's ROE is +0.03%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, ATRC is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
ATRC vs IGAP Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas IGAP's P/E ratio is -10.52. In terms of profitability, ATRC's ROE is +0.03%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, ATRC is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check IGAP's competition here
Daxor Corporation (NASDAQ: DXR)
ATRC vs DXR Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, DXR has a market cap of 49.3M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while DXR trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas DXR's P/E ratio is 6.87. In terms of profitability, ATRC's ROE is +0.03%, compared to DXR's ROE of +0.13%. Regarding short-term risk, ATRC is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check DXR's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
ATRC vs HBIO Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, HBIO has a market cap of 42.2M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while HBIO trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas HBIO's P/E ratio is -25.72. In terms of profitability, ATRC's ROE is +0.03%, compared to HBIO's ROE of -1.30%. Regarding short-term risk, ATRC is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
ATRC vs NEPH Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, NEPH has a market cap of 34.2M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while NEPH trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas NEPH's P/E ratio is 52.50. In terms of profitability, ATRC's ROE is +0.03%, compared to NEPH's ROE of +0.17%. Regarding short-term risk, ATRC is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check NEPH's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
ATRC vs ZJYL Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, ZJYL has a market cap of 33M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while ZJYL trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas ZJYL's P/E ratio is 28.80. In terms of profitability, ATRC's ROE is +0.03%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, ATRC is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check ZJYL's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
ATRC vs SDC Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas SDC's P/E ratio is -0.03. In terms of profitability, ATRC's ROE is +0.03%, compared to SDC's ROE of -1.96%. Regarding short-term risk, ATRC is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check SDC's competition here
Milestone Scientific Inc. (AMEX: MLSS)
ATRC vs MLSS Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, MLSS has a market cap of 27.8M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while MLSS trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas MLSS's P/E ratio is -6.14. In terms of profitability, ATRC's ROE is +0.03%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, ATRC is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check MLSS's competition here
Invacare Corporation (NYSE: IVC)
ATRC vs IVC Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas IVC's P/E ratio is -0.79. In terms of profitability, ATRC's ROE is +0.03%, compared to IVC's ROE of -0.46%. Regarding short-term risk, ATRC is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
ATRC vs RVP Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, RVP has a market cap of 16.6M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while RVP trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas RVP's P/E ratio is -4.62. In terms of profitability, ATRC's ROE is +0.03%, compared to RVP's ROE of -0.05%. Regarding short-term risk, ATRC is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
ATRC vs BNGO Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, BNGO has a market cap of 14.5M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while BNGO trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas BNGO's P/E ratio is -0.41. In terms of profitability, ATRC's ROE is +0.03%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, ATRC is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check BNGO's competition here
Femasys Inc. (NASDAQ: FEMY)
ATRC vs FEMY Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, FEMY has a market cap of 12M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while FEMY trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas FEMY's P/E ratio is -0.32. In terms of profitability, ATRC's ROE is +0.03%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, ATRC is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
ATRC vs RGNT Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, RGNT has a market cap of 9.2M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while RGNT trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas RGNT's P/E ratio is -0.53. In terms of profitability, ATRC's ROE is +0.03%, compared to RGNT's ROE of N/A. Regarding short-term risk, ATRC is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check RGNT's competition here
Lucyd, Inc (NASDAQ: LUCY)
ATRC vs LUCY Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, LUCY has a market cap of 7.5M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while LUCY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas LUCY's P/E ratio is -0.67. In terms of profitability, ATRC's ROE is +0.03%, compared to LUCY's ROE of -1.03%. Regarding short-term risk, ATRC is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
ATRC vs NSTG Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas NSTG's P/E ratio is -0.03. In terms of profitability, ATRC's ROE is +0.03%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, ATRC is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check NSTG's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
ATRC vs CUPR Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, CUPR has a market cap of 4.7M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while CUPR trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas CUPR's P/E ratio is -1.27. In terms of profitability, ATRC's ROE is +0.03%, compared to CUPR's ROE of -0.85%. Regarding short-term risk, ATRC is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check CUPR's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
ATRC vs POAI Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas POAI's P/E ratio is -0.38. In terms of profitability, ATRC's ROE is +0.03%, compared to POAI's ROE of -21.19%. Regarding short-term risk, ATRC is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
ATRC vs MHUA Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas MHUA's P/E ratio is 0.25. In terms of profitability, ATRC's ROE is +0.03%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, ATRC is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
ATRC vs GMVD Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas GMVD's P/E ratio is -0.01. In terms of profitability, ATRC's ROE is +0.03%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, ATRC is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
ATRC vs GMVDW Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas GMVDW's P/E ratio is N/A. In terms of profitability, ATRC's ROE is +0.03%, compared to GMVDW's ROE of +3.68%. Regarding short-term risk, ATRC is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
ATRC vs NXGL Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, NXGL has a market cap of 1.7M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while NXGL trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas NXGL's P/E ratio is -5.06. In terms of profitability, ATRC's ROE is +0.03%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, ATRC is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check NXGL's competition here
Avinger, Inc. (NASDAQ: AVGR)
ATRC vs AVGR Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas AVGR's P/E ratio is -0.05. In terms of profitability, ATRC's ROE is +0.03%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, ATRC is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
ATRC vs NXGLW Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, NXGLW has a market cap of 395.5K. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, ATRC's ROE is +0.03%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, ATRC is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
ATRC vs LUCYW Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas LUCYW's P/E ratio is N/A. In terms of profitability, ATRC's ROE is +0.03%, compared to LUCYW's ROE of -1.03%. Regarding short-term risk, ATRC is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for ATRC.Check LUCYW's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
ATRC vs ATRS Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas ATRS's P/E ratio is 14.95. In terms of profitability, ATRC's ROE is +0.03%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, ATRC is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
ATRC vs IVTY Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas IVTY's P/E ratio is -3.80. In terms of profitability, ATRC's ROE is +0.03%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, ATRC is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check IVTY's competition here
Analogic Corporation (NASDAQ: ALOG)
ATRC vs ALOG Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas ALOG's P/E ratio is 40.93. In terms of profitability, ATRC's ROE is +0.03%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, ATRC is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check ALOG's competition here
Apria, Inc. (NASDAQ: APR)
ATRC vs APR Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, APR has a market cap of 0. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas APR's P/E ratio is 22.59. In terms of profitability, ATRC's ROE is +0.03%, compared to APR's ROE of +9.81%. Regarding short-term risk, ATRC is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
ATRC vs HRC Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas HRC's P/E ratio is 41.92. In terms of profitability, ATRC's ROE is +0.03%, compared to HRC's ROE of +0.14%. Regarding short-term risk, ATRC is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
ATRC vs IIN Comparison November 2026
AtriCure, Inc. (NASDAQ: ATRC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRC stands at 2.9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, ATRC is priced at $56.44 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRC currently has a P/E ratio of 1747.20, whereas IIN's P/E ratio is 226.45. In terms of profitability, ATRC's ROE is +0.03%, compared to IIN's ROE of -0.00%. Regarding short-term risk, ATRC is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for ATRC.Check IIN's competition here